- 1、本文档共55页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
小肠克罗恩病诊断与治疗 ppt课件
* * * * 英夫利西除了前一张幻灯片提到的阻止TNF-a的作用外,还可以通过激活补体和ADCC(抗体依赖性的细胞毒性)作用,特异性溶解产生TNF?的活性细胞(如单核细胞、巨嗜细胞和T细胞),从而从根本上抑制TNF-a的生成。 1.激活补体的作用:英夫利西单抗与TNF-a结合后可以激活补体,补体可以在产生TNF-a的T细胞上打孔,从而溶解T细胞; 2.ADCC作用:英夫利西单抗与TNF-a结合后,抗体的Fc段可与吞噬细胞上的Fc段受体结合,从而激活吞噬细胞,吞噬细胞进而吞噬产生TNF-a的T细胞。 * * Notes: _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ _______________________________________________________ * * The proportion of patients achieving clinical response at Week 10 in pediatric patients (REACH) was 88%. The proportion of patients in clinical response in adult patients (ACCENT I) at Week 10 was 67%. The confidence interval for the proportion of patients in clinical response at Week 10 for the pediatric population in the REACH study lies completely above the confidence interval for the adult population in the ACCENT I study, and on this basis, REACH met its primary endpoint. The study definition of clinical response in REACH was based on the PCDAI score, whereas CDAI was used in ACCENT I. * * The proportion of patients in clinical remission without corticosteroids at Week 30 was 46% for the infliximab q 8 weeks maintenance group and 33% for the q 12 weeks maintenance group. The proportion of patients in clinical remission without corticosteroids at Week 54 was 46% for the infliximab q 8 weeks maintenance group and 17% for the q 12 weeks maintenance group. * * Eighty-one percent of patients treated with a single dose of 类克 5 mg/kg achieved clinical response (decrease in 克罗恩病AI from baseline of ≥ 70 points) by Week 4 compared to 16% of patients tre
文档评论(0)